Measuring treatment satisfaction helps capture an important part of the patient experience in derm. DermSat-7 is a free-to-use, 7-item patient-reported instrument developed for dermatologic conditions & validated in psoriasis & acne.
Access: [email protected]#Dermatology
DEOM will be at Lisbon @GrappaO 2026 🇵🇹
If you’re attending GRAPPA, we’d love to see you at our open IDEOM gathering to connect and advance patient-centered outcomes work together. Find us there!
#GRAPPA#GRAPPA26#IDEOM#Dermatology
Psoriatic disease goes beyond the skin. MSK-Q is a free, validated patient-reported questionnaire capturing MSK symptom burden in psoriasis/PsA: symptom intensity, daily life impact, and fatigue. Validated in 1,453 patients.
Request access: [email protected]#PsA#IDEOM
Free, validated PRO instruments for dermatologic research. IDEOM MSK-Q measures musculoskeletal symptoms and their impact in psoriatic disease. DermSat-7 captures treatment satisfaction across skin conditions.
Request access today!
#Dermatology#ClinicalResearch#Psoriasis
One room. Physicians, patients, researchers, payers, caregivers, nurses & more- all working toward the same goal: evidence-based outcomes measures that actually reflect what matters to patients. Grateful for this community. Here's to another year of progress.
#IDEOM#Dermatology
As we look ahead to our 13th Annual this June, we’re reflecting on progress from last year. The CTCL Workgroup identified 19 candidate health-related quality-of-life concepts through two Delphi rounds for clinical trials in mycosis fungoides and Sézary syndrome.
#Dermatology
Deadline extended to May 15! 📣
Submit your outcomes research abstract for the #IDEOM2026 Annual Meeting (June 19–20, DC). Open to patients, clinicians, trainees & industry — no fee for IDEOM stakeholders.
Submit → https://t.co/3WRdT7rtk3
#DermOutcomes#DermatologyResearch
HS affects more than the skin. At last year's meeting, the HS Workgroup advanced validation of the IDEOM MSK-Q, a tool designed to capture musculoskeletal pain, joint swelling, joint stiffness, fatigue, & functional impact in people living with hidradenitis suppurativa.
#HS
Congratulations to our President, Dr. Alice Gottlieb MD, PhD, on her appointment as VP of the @AADermAssoc! 🎉
Her leadership, vision, and unwavering commitment to patients and the dermatology community make this honor so well deserved. We are incredibly proud!
#MedicalLeadership
Dermatology’s patient population is aging, but many QoL tools still miss what matters most to older adults. The AGED Workgroup is helping close that gap by advancing geriatric-specific outcome measures in dermatology.
#Dermatology#IDEOM
Congrats to Dr. Jaleel on receiving the @dermfoundation – @SkinOfColor Collaborative Mid-Career Award at the 22nd Annual SOCS Scientific Symposium. We’re proud to have her as a leader in IDEOM’s HS Workgroup & celebrate this well-deserved recognition!
#Dermatology#HS
At last year’s meeting, the Psoriatic Disease Workgroup shared progress on DermSat-11, psoriasis remission, IDEOM MSK-Q validation, and better PsA screening + management with PEST and PsAID-12.
More this June at IDEOM’s Annual Meeting!
#Psoriasis#PsA
Up to 41% of psoriatic arthritis cases may go undiagnosed, increasing the risk of joint damage. IDEOM highlights how adding PEST + PsAID-12 to the EMR may support earlier detection and better PsA management.
https://t.co/u1fHsxDEr7
What does meaningful progress in vitiligo research look like? At last year’s IDEOM meeting, the Vitiligo Workgroup validated key domains in the vitiligo model & used them to develop a new patient satisfaction tool focused on experiences existing measures don’t capture.
#Vitiligo
For many patients, itch is the most disruptive part of skin disease. At IDEOM’s meeting, the Itch Workgroup highlighted growing consensus around the WI-NRS as a key measure of patient experience & discussed treating itch as a condition in its own right.
#Dermatology#Itch#IDEOM
Evans Kojo Baffoe shares how he found IDEOM and why he’s advocating for better psoriasis awareness, support, and access to care in Ghana and across Africa.
Watch his full interview: https://t.co/FMGgrvRtzw
#Psoriasis#IDEOM
IDEOM will be at Lisbon GRAPPA 2026 🇵🇹
If you’re attending @GrappaO , we’d love to see you at our open IDEOM gathering to connect and advance patient-centered outcomes work together. Find us there!
#GRAPPA#GRAPPA26#IDEOM#Dermatology
We build patient-centered outcome measures. 2024 Annual Meeting report just published: psoriatic disease work includes PEST + PsAID-12 in 26 clinics to help detect PsA earlier: https://t.co/IOEBqpOljg
#DermResearch
WG: @JosephMerolaMD, @_AprilArmstrong, Perez-Chada, & Gottlieb
At IDEOM, we don’t just develop outcome measures, we build the ecosystem that makes them meaningful.
Patients, researchers, payers & clinicians all have a seat at the table.
And yes, our tools are always free to use!
#PatientCenteredCare#DermTwitter